Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma Holdings (NASDAQ:ASBP) has completed patient dosing in its Phase 1 clinical trial for its oral transmucosal fast-acting high-dose aspirin formulation. The study compares the company's sublingual 162.5 mg aspirin powder against traditional oral aspirin in healthy adult volunteers.
The trial evaluates plasma acetylsalicylic acid concentration, Arachidonic acid-induced platelet aggregation, and Serum thromboxane B2 measurements to assess the formulation's rapid impact on cardiac events. Topline results are expected by mid-Q3 2025, after which Aspire plans to pursue a section 505(b)(2) NDA and explore potential partnership opportunities.
Aspire Biopharma Holdings (NASDAQ:ASBP) ha completato la somministrazione ai pazienti nella sua sperimentazione clinica di Fase 1 per la formulazione orale transmucosa ad azione rapida di aspirina ad alto dosaggio. Lo studio confronta la polvere sublinguale di aspirina da 162,5 mg dell'azienda con l'aspirina orale tradizionale in volontari adulti sani.
La sperimentazione valuta la concentrazione plasmatica di acido acetilsalicilico, l'aggregazione piastrinica indotta da acido arachidonico e le misurazioni del trombossano B2 nel siero per analizzare l'impatto rapido della formulazione sugli eventi cardiaci. I risultati principali sono attesi entro la met脿 del terzo trimestre 2025, dopo di che Aspire prevede di presentare una NDA ai sensi della sezione 505(b)(2) ed esplorare potenziali opportunit脿 di partnership.
Aspire Biopharma Holdings (NASDAQ:ASBP) ha completado la dosificaci贸n de pacientes en su ensayo cl铆nico de Fase 1 para su formulaci贸n oral transmucosal de aspirina de alta dosis y acci贸n r谩pida. El estudio compara el polvo sublingual de aspirina de 162,5 mg de la compa帽铆a frente a la aspirina oral tradicional en voluntarios adultos sanos.
El ensayo eval煤a la concentraci贸n plasm谩tica de 谩cido acetilsalic铆lico, la agregaci贸n plaquetaria inducida por 谩cido araquid贸nico y las mediciones de tromboxano B2 en suero para valorar el impacto r谩pido de la formulaci贸n en eventos card铆acos. Se esperan resultados principales para mediados del tercer trimestre de 2025, tras lo cual Aspire planea presentar una NDA bajo la secci贸n 505(b)(2) y explorar posibles oportunidades de colaboraci贸n.
Aspire Biopharma Holdings (NASDAQ:ASBP)電� 瓴疥惮 鞝愲 韴臣 瓿犾毄霟� 鞎勳姢頂茧Π 鞁犾啀 鞛戩毄 鞝滍槙鞐� 雽�頃� 1靸� 鞛勳儊鞁滍棙鞐愳劀 頇橃瀽 韴暯鞚� 鞕勲頄堨姷雼堧嫟. 氤� 鞐瓣惮電� 須岇偓鞚� 靹ろ晿 162.5mg 鞎勳姢頂茧Π 攵勲鞚� 鞝勴喌鞝侅澑 瓴疥惮 鞎勳姢頂茧Π瓿� 瓯搓皶頃� 靹膘澑 鞛愳洂氪夓偓鞛愲ゼ 雽�靸侅溂搿� 牍勱祼頃╇媹雼�.
鞁滍棙鞚� 順堨灔 鞎勳劯韹胳偞毽嫟靷� 雴嶋弰, 鞎勲澕韨る張靷� 鞙犽弰 順堨唽韺� 鞚戩, 順堨箔 韸鸽‖氤奠偘 B2 旄§爼鞚� 韽夑皜頃橃棳 鞝滍槙鞚� 鞁灔 靷贝鞐� 氙胳箻電� 鞁犾啀頃� 鞓來枼鞚� 攵勳劃頃╇媹雼�. 欤检殧 瓴瓣臣電� 2025雲� 3攵勱赴 欷戨皹旯岇 氚滍憸霅� 鞓堨爼鞚措┌, 鞚错泟 Aspire電� 505(b)(2) 靹轨厴鞐� 霐半ジ NDA毳� 於旍頃橁碃 鞛犾灛鞝� 韺岉姼雱堨嫮 旮绊殞毳� 氇儔頃� 瓿勴殟鞛呺媹雼�.
Aspire Biopharma Holdings (NASDAQ:ASBP) a termin茅 le dosage des patients dans son essai clinique de phase 1 pour sa formulation orale transmucosale d'aspirine 脿 haute dose 脿 action rapide. L'茅tude compare la poudre d'aspirine sublinguale de 162,5 mg de la soci茅t茅 脿 l'aspirine orale traditionnelle chez des volontaires adultes en bonne sant茅.
L'essai 茅value la concentration plasmatique d'acide ac茅tylsalicylique, l'agr茅gation plaquettaire induite par l'acide arachidonique, ainsi que les mesures du thromboxane B2 s茅rique afin d'appr茅cier l'impact rapide de la formulation sur les 茅v茅nements cardiaques. Les r茅sultats principaux sont attendus d'ici la mi-T3 2025, apr猫s quoi Aspire pr茅voit de d茅poser une NDA selon la section 505(b)(2) et d'explorer des opportunit茅s de partenariat potentielles.
Aspire Biopharma Holdings (NASDAQ:ASBP) hat die Patientendosierung in seiner Phase-1-Studie f眉r die orale transmukosale, schnell wirkende Hochdosis-Aspirin-Formulierung abgeschlossen. Die Studie vergleicht das sublinguale Aspirin-Pulver mit 162,5 mg des Unternehmens mit herk枚mmlichem oralem Aspirin bei gesunden erwachsenen Freiwilligen.
Die Studie bewertet die Plasmakonzentration von Acetylsalicyls盲ure, arachidoninduzierte Thrombozytenaggregation und Serum-Thromboxan-B2-Messungen, um die schnelle Wirkung der Formulierung auf kardiale Ereignisse zu beurteilen. Die Hauptergebnisse werden Mitte Q3 2025 erwartet, danach plant Aspire die Einreichung eines NDA gem盲脽 Abschnitt 505(b)(2) und die Erkundung potenzieller Partnerschaftsm枚glichkeiten.
- Clinical trial patient dosing completed on schedule according to protocol
- Company plans to submit 505(b)(2) NDA for market approval
- Management actively pursuing potential partnership opportunities
- None.
Insights
Aspire Biopharma completes Phase 1 dosing on schedule; key efficacy data for fast-acting aspirin formulation expected Q3 2025.
Aspire Biopharma has achieved a noteworthy operational milestone with the completion of patient dosing in their Phase 1 trial for a novel sublingual high-dose aspirin formulation. The study's design focuses on comparing their 162.5 mg sublingual powder against traditional oral aspirin, with primary endpoints examining plasma concentration kinetics over 24 hours post-administration.
The trial includes critical secondary measurements of platelet aggregation and serum thromboxane B2 levels over 8 hours鈥攂iomarkers that will directly demonstrate if their formulation achieves the rapid onset needed for acute cardiac events. This speed-of-action advantage would be the key differentiator for their product.
From a regulatory perspective, Aspire's planned 505(b)(2) NDA pathway is strategically sound for reformulated products, potentially enabling a more streamlined approval process by leveraging established safety data for aspirin. This approach balances efficiency with lower development costs compared to novel compounds.
While meeting enrollment timelines demonstrates operational competence, investors should recognize that as a Phase 1 study, this trial primarily establishes basic pharmacokinetics and safety rather than definitive efficacy. The true inflection point will come with the Q3 data readout, which will determine whether the formulation achieves the rapid absorption profile necessary to support its value proposition in emergency cardiac care.
The management's mention of potential partnership discussions signals confidence in their preliminary data and recognition that commercializing an emergency cardiac medication would benefit from established distribution channels and sales infrastructure that strategic partners could provide.
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025
ESTERO, FL AND NEW YORK, NY / / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the last patient was dosed in its Phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation.
Topline results from the study are anticipated by the middle of third quarter of 2025.
"The successful completion of patient dosing in our Phase 1 trial is a noteworthy accomplishment. We are extremely grateful to the investigator and patients who participated in this study. Achieving this milestone on time and as planned per protocol also demonstrates the operational excellence of our team and clinical partners," said Michael Howe, Chief Executive Officer of Aspire. "We look forward to reporting initial safety and efficacy data in the third quarter, which will provide key insights into our formulation of high-dose aspirin and its potential as a fast-acting treatment option for suspected acute myocardial infarction. Following the receipt of the topline results, we plan to continue discussions with the FDA to ensure our path forward is well-aligned with regulatory expectations."
Howe added, "We are eager to integrate the insights from this trial into our comprehensive development plan. We believe these trial results will also play a key role in our strategy to pursue potential partnership opportunities."
Phase 1 Study Design
The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the administration of our sublingual dose of 162.5 mg aspirin powder with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post-dose). The trial also measures Arachidonic acid (AA)-induced platelet aggregation over 8 hours after dosing and Serum thromboxane B2 (TxB2) over 8 hours after dosing, both of which are valuable for documenting Aspire's sublingual high-dose aspirin's rapid impact on cardiac events.
Following completion of this trial, Aspire plans to submit a section 505(b)(2) NDA seeking approval to market the high-dose aspirin product.
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers a soluble, fast-acting granular or powder formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of drugs and other substances. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities.
About Aspire Biopharma, Inc.
Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit .
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]
SOURCE: Aspire Biopharma Holdings, Inc.
View the original on ACCESS Newswire
FAQ
When will Aspire Biopharma (ASBP) release Phase 1 trial results for its fast-acting aspirin?
What is the dosage of Aspire Biopharma's (ASBP) sublingual aspirin formulation?
What regulatory pathway is Aspire Biopharma (ASBP) pursuing for its high-dose aspirin product?
What is the purpose of Aspire Biopharma's (ASBP) new aspirin formulation?
What endpoints are being measured in Aspire Biopharma's (ASBP) Phase 1 aspirin trial?
